Skip to main content

Table 1 Clinico-pathological and outcome data corresponding to the pancreatic cancer tissue microarray training and validation sets, and the prospective ICGC cohort gene expression array

From: RON is not a prognostic marker for resectable pancreatic cancer

 

Training Cohort

Validation Cohort

ICGC Cohort

Variables

n = 76 No. (%)

Median DSS (months)

P value (Logrank)

n = 316 No. (%)

Median DSS (months)

P value (Logrank)

n = 100 No. (%)

Median DSS (months)

P value (Logrank)

Sex

         

  Male

45 (59.2)

16.3

 

157 (49.7)

18.3

 

61 (61.0)

18.4

 

  Female

31 (40.8)

8.5

0.0340

159 (50.3)

16.9

0.5792

39 (39.0)

18.3

0.5467

Age (years)

         

  Mean

62.1

  

66.7

  

66.9

  

  Median

64.5

  

69.0

  

68.0

  

  Range

35.0 – 83.0

  

28.0 – 87.0

  

34.0 – 90.0

  

Outcome

         

  Follow-up (months)

0.3 – 158.0

  

0.1 – 195.8

  

0.1 – 29.8

  

  Median follow-up

158.0

  

68.7

  

14.1

  

  Death PC

68 (89.5)

  

259 (82.0)

  

33 (33.0)

  

  Death other

5 (6.6)

  

15 (4.7)

  

9 (9.0)

  

  Death Unknown

0 (0.0)

  

3 (0.9)

  

3 (3.0)

  

  Alive

1 (1.3)

  

38 (12.0)

  

55 (55.0)

  

  Lost to FU

2 (2.6)

  

1 (0.3)

  

0 (0.0)

  

Stage a

         

  I

16 (21.1)

19.6

 

23 (7.3)

41.0

 

8 (8.0)

17.4

 

  II

59 (77.6)

11.5

 

282 (89.2)

17.8

 

87 (87.0)

18.8

 

  III

0 (0.0)

  

0 (0.0)

  

1 (1.0)

----b

 

  IV

1 (1.3)

22.0

0.2828

11 (3.5)

7.6

<0.0001

4 (4.0)

12.0

****c

T Stage

         

  T1

12 (15.8)

  

16 (5.1)

  

3 (3.0)

  

  T2

29 (38.2)

13.6

 

33 (10.4)

26.6

 

12 (12.0)

17.4

 

  T3

35 (46.1)

14.7

0.4857

267 (84.5)

16.8

0.0084

84 (84.0)

  

  T4

0 (0.0)

  

0 (0.0)

  

1 (1.0)

18.4

0.4297

N Stage

         

  N0

37 (48.7)

19.8

 

119 (37.7)

21.2

 

24 (24.2)

17.4

 

  N1

39 (51.3)

9.7

<0.0001

197 (62.3)

16.7

0.0267

75 (75.8)

18.4

0.4714

Grade

         

  I

7 (9.2)

  

26 (8.2)

  

4 (4.0)

  

  II

43 (56.6)

15.0

 

209 (66.1)

17.7

 

61 (61.0)

----

 

  III

26 (34.2)

11.2

0.0283

81 (25.6)

18.3

0.5971

33 (33.0)

  

  IV

      

2 (2.0)

15.1

0.0011

Tumor size

         

  ≤ 20 mm

15 (19.7)

17.1

 

77 (24.6)

32.0

 

14 (14.0)

18.3

 

  > 20 mm

61 (80.3)

11.9

0.1232

236 (75.4)

16.0

<0.0001

86 (86.0)

18.4

0.8056

Margins

         

  Clear

40 (52.6)

18.6

 

195 (61.7)

22.4

 

66 (66.0)

----

 

  Involved

36 (47.4)

9.7

0.0004

121 (38.3)

13.3

<0.0001

34 (34.0)

13.9

0.0335

Tumor Location

         

  Head

62 (81.6)

15.6

 

258 (81.6)

18.8

 

85 (85.0)

18.4

 

  Others

14 (18.4)

7.4

0.0004

58 (18.4)

13.0

0.0312

15 (15.0)

13.6

0.0488

Perineural Invasion

         

  Negative

24 (32.0)

15.6

 

82 (26.6)

25.6

 

20 (20.6)

----

 

  Positive

51 (68.0)

13.6

0.1909

226 (73.4)

17.4

0.1180

77 (79.4)

17.4

0.0211

Vascular Invasion

         

  Negative

45 (60.0)

15.0

 

161 (53.5)

21.2

 

39 (40.6)

----

 

  Positive

30 (40.0)

10.1

0.0141

140 (46.5)

16.2

0.0070

57 (59.4)

15.9

0.0348

Adj Chemotherapy

         

  Yes

13 (17.1)

13.6

 

98 (31.0)

22.4

 

65 (68.4)

21.4

 

  No

63 (82.9)

14.1

0.7737

218 (69.0)

16.5

0.0451

30 (31.6)

12.0

0.0007

RON Expression d

         

  Low or absent

51 (79.7)

15.0

 

265 (94.3)

17.1

 

42 (52.5)

9.8

 

  High

13 (20.3)

6.4

0.0409

16 (5.7)

18.3

0.2799

38 (47.5)

8.0

0.3830

  1. Patient Cohorts Characteristics.
  2. a AJCC 7th Edition.
  3. b Median survival has not been reached yet.
  4. c Rank test cannot be tested as one or more groups contained no censored observations.
  5. d High RON expression was defined as H > 210 for immunohistochemistry or greater than 8.74 on normalized Log2 score for gene expression array.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us